GOSS

Gossamer Bio, Inc. operates as a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in immunology, inflammation, and oncology. Headquartered in San Diego, California, the company advances a pipeline of product candidates targeting diseases with significant unmet medical needs. Gossamer's lead programs include seralutinib, an inhaled therapy in Phase 3 development for pulmonary arterial hypertension and other pulmonary conditions, and GB002 (beremagene geperpavec), a gene therapy for recessive dystrophic epidermolysis bullosa. The company also develops GB004, a T-cell receptor engineered cell therapy for synovial sarcoma and myxoid round cell liposarcoma. Founded in 2015 by Faheem Hasnain and a team of industry veterans from Receptos, Gossamer went public in 2019. The company employs approximately 200 people and maintains research operations in San Diego. In recent developments, Gossamer reported positive data from seralutinib's Phase 2 TORREY trial and advanced GB002 through clinical trials following its acquisition of Xalud Therapeutics in 2021. The company focuses on precision medicine approaches and targets patient populations where current treatment options remain limited. Gossamer funds operations primarily through equity financings and strategic partnerships while maintaining no marketed products as of 2024.